| Literature DB >> 31674937 |
Buğra Özkan1, Özcan Örsçelik1, Hatice Yıldırım Yaroğlu2, Şenay Balcı2, Mert Koray Özcan1, Ahmet Çelik1, Ismail Türkay Özcan1.
Abstract
OBJECTIVE: Dilation of one or more coronary artery segments to a diameter at least 1.5 times that of a normal adjacent segment is referred to as coronary artery ectasia (CAE). Adropin is a protein involved in endothelial function and is shown to have a protective effect on the regulation of cardiac functions. Atherosclerosis and endothelial dysfunction play an important role in the development of CAE. The aim of this study was to investigate the association between serum adropin levels and isolated CAE.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31674937 PMCID: PMC6955056 DOI: 10.14744/AnatolJCardiol.2019.90349
Source DB: PubMed Journal: Anatol J Cardiol ISSN: 2149-2263 Impact factor: 1.596
Comparison of basic clinical features of patients and controls
| Variables | Isolated CAE group (n=40) | Control group (n=52) | |
|---|---|---|---|
| Sex (n, %) males | 27 (67.5) | 30 (57.7) | 0.392 |
| Age (year) | 56.9±7.6 | 55.2±10.2 | 0.364 |
| Diabetes mellitus, % | 8 (20) | 12 (23.1) | 0.723 |
| Hypertension, % | 12 (30) | 13 (25) | 0.593 |
| Hyperlipidemia, % | 8 (20) | 8 (15.4) | 0.563 |
| Smoking, % | 9 (22.5) | 13 (25) | 0.780 |
| ACEI/ARB use, % | 6 (15) | 9 (17.3) | 0.758 |
| CCB use, % | 7 (17.5) | 6 (11.5) | 0.414 |
| BB use, % | 6 (15) | 6 (11.5) | 0.091 |
| Aspirin use,% | 11 (27.5) | 9 (17.3) | 0.240 |
| Statin use, % | 7 (17.5) | 6 (11.5) | 0.416 |
| BMI (kg/m2) | 26.2±2.4 | 25.5±2.1 | 0.154 |
| Markis classification | |||
| Type 1, % | 6 (15) | ||
| Type 2, % | 17 (42.5) | ||
| Type 3, % | 13 (32.5) | ||
| Type 4, % | 4 (10) |
ACEI - angiotensin converting enzyme; ARB - angiotensin receptor blocker;
BB - beta blocker; BMI - body mass index; CCB - calcium canal blocker
Biochemical features of patients and controls
| Variables | Isolated CAE group (n=40) | Control group (n=52) | |
|---|---|---|---|
| Creatinin (mg/dL) | 0.85±0.17 | 0.83±0.16 | 0.688 |
| Na (mg/dL) | 140.0±4.0 | 140.4±2.7 | 0.892 |
| K (mg/dL) | 4.40±0.49 | 4.44±0.38 | 0.674 |
| MPV (fL) | 10.75±0.78 | 10.17±0.76 | |
| WBC (103/µL) | 7.80±1.92 | 7.60±1.80 | 0.863 |
| HDL (mg/dL) | 41.30±12.30 | 45.03±8.29 | 0.084 |
| LDL (mg/dL) | 106.51±31.20 | 113.98±31.80 | 0.266 |
| TG (mg/dL) | 174.72±74.40 | 168.92±56.75 | 0.773 |
| LVEF (%) | 56.20±3.76 | 57.4±3.41 | 0.091 |
| SBP (mm Hg) | 127.00±7.25 | 125.51±6.32 | 0.293 |
| DBP (mm Hg) | 80.42±4.66 | 80.88±4.19 | 0.624 |
| Adropin (pg/mL) | 1019.57±271.01 | 1151.1±212.63 | |
| Neutrophil to lymphocyte ratio | 2.26±1.86 | 2.08±0.71 | 0.402 |
MPV - mean platelet volume; WBC - white blood cell; HDL - high-density lipoprotein; LDL - low-density lipoprotein; TG - triglycerides; LVEF - left ventricular ejection fraction; SBP - systolic blood pressure; DBP - diastolic blood pressure
Figure 1Receiver operating characteristic curve for the determination of the cut-off for adropin level and coronary artery ectasia
Univariate test results
| Coeff. | Standard error | Odds ratio | CI lower limit | CI upper limit | ||
|---|---|---|---|---|---|---|
| Adropin | -0.262 | 0.001 | 0.965 | 0.940 | 0.989 | |
| MPV | 0.959 | 0.302 | 2.610 | 1.443 | 4.721 | |
| HDL | -0.040 | 0.024 | 0.093 | 0.961 | 0.917 | 1.007 |
| BMI | 0.134 | 0.094 | 0.153 | 1.144 | 0.951 | 1.375 |
| LVEF | -0.102 | 0.061 | 0.093 | 0.903 | 0.802 | 1.017 |
| Use of BB | 0.938 | 0.567 | 0.098 | 2.556 | 0.841 | 7.768 |
BB - beta blocker; Coeff. - coefficient expressed in logits; CI - 95% confidence interval for the odds, MPV - mean platelet volume; HDL - high-density lipoprotein; BMI - body mass index; LVEF - left ventricular ejection fraction
Multiple variable test results
| Coeff. | Standard error | Odds ratio | CI lower limit | CI upper limit | ||
|---|---|---|---|---|---|---|
| Adropin | -0.003 | 0.001 | 0.897 | 0.865 | 0.949 | |
| MPV | 1.109 | 0.339 | 3.033 | 1.526 | 5.889 |
Coeff. - coefficient expressed in logits; CI - 95% confidence interval for the odds; MPV - mean platelet volume